Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
· OX124 is based on Orexo´s world-class drug delivery platform amorphOX® and is designed to reverse the effect of the most powerful synthetic opioids, such as fentanyl · Synthetic opioids are behind 91 percent of all fatal opioid overdoses in the US[1] · If approved, US launch is expected to be initiated late in H2 2024 or early 2025 Uppsala, Sweden – September 18, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OX124, a high-dose rescue medication for opioid